Sanghuangporus Sanghuang Supplementation to Improve Anti-Fatigue Performance in Healthy Adults
Clinical Evaluation of Sanghuangporus Sanghuang in Anti-fatigue
National Taiwan Sport University
60 participants
Apr 7, 2025
INTERVENTIONAL
Conditions
Summary
This clinical study aims to evaluate the anti-fatigue and muscle performance-enhancing effects of Sanghuangporus sanghuang mycelia (SS-MN4) capsules in healthy adults. As muscle mass and function naturally decline with age or sedentary lifestyle, there is growing interest in nutritional interventions that may help preserve physical performance and reduce fatigue. Sanghuangporus sanghuang, a traditional medicinal fungus, contains bioactive compounds such as hispidin, known for their antioxidant and anti-inflammatory properties. The study is a randomized, double-blind, placebo-controlled trial involving 60 healthy male participants aged 20 to 35 years with no regular exercise habits. Participants will be randomly assigned to receive either SS-MN4 capsules (1000 mg/day) or a placebo for 42 days. The intervention aims to determine whether SS-MN4 improves exercise performance, muscle strength, and biochemical markers related to fatigue and muscle damage. Throughout the study, blood samples, urine samples, exercise tests (e.g., anaerobic power, isometric strength), and body composition analyses (DEXA) will be conducted at multiple time points, including before, during, and after the intervention. In addition, intestinal microbiota analysis and nutritional intake records will be included to assess secondary outcomes. This research will provide scientific evidence for the health benefits of SS-MN4 in reducing exercise-induced fatigue and improving muscle function. The data collected may support future applications for anti-fatigue health food certification in Taiwan and the development of novel functional supplements for global markets.
Eligibility
Inclusion Criteria7
- Healthy male participants aged between 20 and 35 years
- Non-smokers and non-drinkers
- Not currently taking any dietary supplements or medications
- Normal liver and kidney function
- No chronic diseases such as cardiovascular disease
- Willing and able to provide written informed consent
- Able to comply with study procedures and schedule
Exclusion Criteria7
- Current or past diagnosis of any cardiovascular, liver, kidney, or metabolic disease
- Regular use of dietary supplements, sports nutrition products, or energy drinks
- Known food allergies or intolerances, particularly to mushrooms or herbal products
- Engaging in regular resistance or endurance training in the last 6 months
- Currently taking medications that may interfere with study outcomes
- Smoking or alcohol consumption
- Participation in other clinical trials within the last 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants in the SS-MN4 group will take 2 capsules daily containing a total of 1000 mg/day of Sanghuangporus sanghuang mycelia extract for 42 consecutive days. The capsules are identical in appearance to the placebo.
Participants in the placebo group will take 2 capsules daily of an inert substance designed to match the SS-MN4 capsules in color, taste, and appearance. The placebo contains no active ingredients and will be taken for 42 consecutive days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06902662